Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
2022 events¹ (expected)
Regulatory
decisions
NME Lead
H1 Pluvicto™ mCRPC (US/EU)
H1
VijoiceⓇ PROS (US✓)
H2
ScemblixⓇ 3L CML (JP/EU)
H2
tislelizumab ESCC 2L (US) 10
H1/H2 JakaviⓇ acute & chronic GVHD (EU /JP)
H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU ✓ /JP✓ )
H1/H2 BeovuⓇ DME (US/EU ✓ /JP✓)
Submissions
H1
ensovibep COVID-19 (US ✓)
H1/H2 CosentyxⓇ HS (EU/US ✓)
H1/H2 tislelizumab NSCLC (EU/US x²)
tislelizumab 1L Nasopharyngeal cancer (US x2)
Cosentyx® Psoriatic Arthritis IV (US)
canakinumab NSCLC Ph3 CANOPY-A (PE not met)
H2
H2
Submissions-
H2
enabling
H2
readouts
TM
H2
Pluvicto pre-taxane mCRPC Ph3 PSMAfore³
iptacopan PNH Ph3 APPLY-PNH✓
References
Abbreviations
✓ Achieved to plan × Not achieved to plan
Other readouts
H1
sabatolimab HR-MDS Ph2 √4
H1
CosentyxⓇ Lichen planus Ph2 PRELUDE5 ✓ (PE not met)
H1
Cosentyx® axSpA IV Ph3 INVIGORATE-1 ✓
H1
icenticaftor COPD Ph2b √6
H2
UNR844 presbyopia Ph2 READER (PE not met)
Ph3/pivotal study
starts
H1
CosentyxⓇ peripheral SpA x7
H1
OAV101 SMA IT STEER ✓
H1
ensovibep COVID-19 (EMPATHY Part B) x8
H2
JDQ443 NSCLC mono ✓
H2
ianalumab Sjögren's Syndrome ✓
H2
ianalumab Lupus Nephritis ✓
H2
ociperlimab solid tumors
H2
TM
Pluvicto nmCRPC x11
H2
YTB323 2L DLBCL⁹
H2
OAV101 SMA IT Ph3b STRENGTH
PE: Primary Endpoint Note: KisqaliⓇ NATALEE Ph3 readout removed (2023 event as shared at Q1 2023) 1. Selected. 2. No US submission planned. 3. Could move to early 2023. 4. Submission will be based on Ph3 results.
5. Primary endpoint at Wk16 not met. 6. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022. Out-licensing planned. 7. Strategy update. 8. No definite start date for the IV Ph3 clinical
trial can be provided at this time. 9. Development strategy being updated. 10. FDA deferred action pending completion of required inspections. 11. Ph3 in nmCRPC shifting to Ph2, with FPFV in 2023.
33 Investor Relations | Q3 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation